CT Imaging Biomarkers Predict Clinical Outcomes after Pancreatic Cancer Surgery

Liang Zhu,Xiaohua Shi,Huadan Xue,Huanwen Wu,Ge Chen,Hao Sun,Yonglan He,Zhengyu Jin,Zhiyong Liang,Zhuoli Zhang
DOI: https://doi.org/10.1097/md.0000000000002664
IF: 1.6
2016-01-01
Medicine
Abstract:Abstract This study aimed to determine whether changes in contrast-enhanced computed tomography (CT) parameters could predict postsurgery overall and progression-free survival (PFS) in pancreatic cancer patients. Seventy-nine patients with a final pathological diagnosis of pancreatic adenocarcinoma were included in this study from June 2008 to August 2012. Dynamic contrast-enhanced (DCE) CT of tumors was obtained before curative-intent surgery. Absolute enhancement change (AEC) and relative enhancement change (REC) were evaluated on DCE-CT. PFS and overall survival (OS) were compared based on CT enhancement patterns. The markers of fibrogenic alpha-smooth muscle antigen (&agr;-SMA) and periostin in tumor specimens were evaluated by immunohistochemical staining. The &khgr;2 test was performed to determine whether CT enhancement patterns were associated with &agr;-SMA-periostin expression levels (recorded as positive or negative). Lower REC (<0.9) was associated with shorter PFS (HR 0.51, 95% CI: 0.31–0.89) and OS (HR 0.44, 95% CI: 0.25–0.78). The &agr;-SMA and periostin expression level were negatively correlated with REC (both P = 0). Among several CT enhancement parameters, REC was the best predictor of patient postsurgery survival. Low REC was associated with a short progression-free time and poor survival. The pathological studies suggested that REC might be a reflection of cancer fibrogenic potential.
What problem does this paper attempt to address?